2000
DOI: 10.1016/s0169-5002(00)80038-0
|View full text |Cite
|
Sign up to set email alerts
|

The relationship between HER2/neu expression and drug resistance for non-small cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Previous studies have shown that HER2 gene amplification was present in 10-20% of NSCLC patients (6,7). Notably, HER2 amplification rates have been shown to be associated with the drug resistance in NSCLC (8,9). At present, the clinical detection of HER2 amplification is generally by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) (10).…”
Section: Introductionmentioning
confidence: 99%
“…Previous studies have shown that HER2 gene amplification was present in 10-20% of NSCLC patients (6,7). Notably, HER2 amplification rates have been shown to be associated with the drug resistance in NSCLC (8,9). At present, the clinical detection of HER2 amplification is generally by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) (10).…”
Section: Introductionmentioning
confidence: 99%